NAFDAC Market Entry and Lifecycle Compliance

The National Agency for Food and Drug Administration and Control (NAFDAC) regulates the manufacture, importation, exportation, distribution, advertisement, sale, and use of regulated products in Nigeria.¹ Its remit includes drugs, vaccines and biologicals, medical devices, in vitro diagnostics, food, cosmetics, chemicals, detergents, and packaged water. For market entrants, NAFDAC engagement is therefore a product-lifecycle relationship rather than a single registration event.

For companies planning market entry or product expansion, this work is closely connected to NAFDAC registration support, regulatory consulting, and pharmacovigilance functions that keep local requirements, submission timing, and lifecycle obligations aligned.

Match the product to the correct route

The first decision is regulatory classification. Product type determines the responsible directorate, evidence standard, application route, inspection needs, sampling or testing, labelling requirements, and post-market obligations. NAFDAC’s online guideline repository should be checked at the start of each programme.²

For imported human and veterinary medicines, current guidance requires dossier screening clearance and submission through NAPAMS, with separate applications for individual products.³ Other product classes have their own current guidelines. Reusing a medicine checklist for a device, supplement, or cosmetic creates preventable gaps.

Registration is evidence plus execution

A technically complete dossier must remain consistent with legal documents, manufacturing information, labels, samples, and the product that will be supplied. Depending on product and pathway, NAFDAC activities may include document verification, GMP or facility assessment, sampling, laboratory analysis, and review by an approval committee.

The Agency’s service page states that drug registration and major variations are completed within 240 working days from acceptance, excluding delays caused by the client.⁴ Organisations should plan the full end-to-end period, including preparation, dossier screening, questions, inspection, testing, certificate issuance, importation, and operational launch.

Clinical development requires separate authorisation

Product registration and clinical trial authorisation are related but distinct processes. NAFDAC states that no clinical trial should commence without written authorisation and that trials should follow the approved protocol, Good Clinical Practice, and Agency requirements.⁵ Favourable ethics review is also required under the applicable Nigerian framework.

Sponsors should use the current clinical trial application, protocol, investigational-product, progress-reporting, and GCP guidance. Site capacity, participant protection, safety reporting, investigational-product control, and reliable documentation remain relevant after authorisation.

Approval creates continuing obligations

After registration, the authorised product and approved information become the controlled baseline. Manufacturing, composition, specifications, sites, labelling, packaging, shelf life, or other changes may require notification, minor variation, major variation, or a new application under the applicable guideline.⁶ Changes should not be implemented solely because they were approved in another country.

Registration certificates require timely renewal. Pharmacovigilance systems must capture and evaluate safety information, and local QPPV expectations apply to relevant certificate holders. Advertising requires its own compliance assessment and, where applicable, approval. Distribution should preserve product quality and traceability.

Post-market evidence can change the product’s status

NAFDAC monitors regulated products through pharmacovigilance, post-market surveillance, complaints, testing, inspections, alerts, and recalls. The Agency publishes products whose market authorisations have been withdrawn, suspended, or cancelled, and NAPAMS provides a product-verification function.^7,8

A company should maintain complaint handling, batch traceability, safety escalation, recall procedures, and a process for reviewing public alerts. NAFDAC’s recall guideline recognises voluntary action by a manufacturer, market authorisation holder, or agent when quality, safety, or efficacy concerns arise.⁹ Rapid, evidence-based action can reduce patient risk and the scale of a market intervention.

Build a local regulatory operating model

An effective Nigeria model connects regulatory affairs, quality, pharmacovigilance, medical, supply, distributors, and commercial teams. It should maintain a product register, obligation calendar, approved-artwork library, variation history, safety commitments, partner responsibilities, renewal dates, and current NAFDAC correspondence.

Market access is sustainable when the locally supplied product continues to match its authorisation, new evidence is evaluated, changes are controlled, and records are ready for regulatory review. Registration opens the market; lifecycle discipline keeps the product compliant within it.

References

1. National Agency for Food and Drug Administration and Control. About NAFDAC. Accessed July 18, 2026. https://nafdac.gov.ng/about-nafdac/
2. National Agency for Food and Drug Administration and Control. Regulatory resources: guidelines. Accessed July 18, 2026. https://nafdac.gov.ng/regulatory-resources/guidelines/
3. National Agency for Food and Drug Administration and Control. Guidelines for registration of imported drug products in Nigeria: human and veterinary drugs. Effective January 8, 2025. Accessed July 18, 2026. https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/DR_And_R_Guidelines/Guidelines-for-Registration-of-Imported-Drug-Products-in-Nigeria-Human-and-Veterinary-Drugs.pdf
4. National Agency for Food and Drug Administration and Control. Product registration and regulation. Accessed July 18, 2026. https://nafdac.gov.ng/our-services/product-registrationevaluation/
5. National Agency for Food and Drug Administration and Control. Clinical trial regulation. Accessed July 18, 2026. https://nafdac.gov.ng/drugs/clinical-trial-regulation/
6. National Agency for Food and Drug Administration and Control. Guidelines on variations to a registered pharmaceutical product. Effective August 29, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/DR_And_R_Guidelines/Guidelines-on-Variation-to-Registered-Pharmaceutical-Product.pdf
7. National Agency for Food and Drug Administration and Control. Market authorization withdrawal. Accessed July 18, 2026. https://nafdac.gov.ng/
8. National Agency for Food and Drug Administration and Control. NAFDAC Automated Product Administration and Monitoring System. Accessed July 18, 2026. https://registration.nafdac.gov.ng/
9. National Agency for Food and Drug Administration and Control. Guidelines for the recall of defective medical products. Effective September 30, 2024. Accessed July 18, 2026. https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PMS_Guidelines_2024/NAFDAC-Guidelines-for-the-Recall-of-Defective-Medical-Products.pdf